Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
US Department of Justice
AstraZeneca
QuintilesIMS
Chinese Patent Office
Cerilliant
Johnson and Johnson
Novartis
Julphar
Chubb

Generated: August 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,115,634 protect, and when does it expire?


Patent ► Subscribe protects NUPLAZID and is included in one NDA.

This patent has twenty-six patent family members in twenty-one countries.

Summary for Patent: ► Subscribe

Title:4-aminopiperidine and their use as a medicine
Abstract: A subject of the present application is new derivatives of 4-aminopiperidines of formula ##STR00001## in which R.sub.1, R.sub.2 and R.sub.3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
Inventor(s): Thurieau; Christophe (Paris, FR), Gonzalez; Jerome (Annemasse, FR), Moinet; Christophe (Montreal, CA)
Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (FR)
Application Number:10/130,924
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France99 15724Dec 14, 1999
PCT Information
PCT FiledDecember 13, 2000PCT Application Number:PCT/FR00/03497
PCT Publication Date:June 21, 2001PCT Publication Number: WO01/44191

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,393,861Derivatives of 4-aminopiperidine and their use as a medicament► Subscribe
8,110,574Derivatives of 4-aminopiperidine and their use as a medicament► Subscribe
7,858,789Derivatives of 4-aminopiperidine and their use as a medicament► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1207283► Subscribe
Cyprus1108415► Subscribe
Czech Republic305360► Subscribe
Germany60039539► Subscribe
Denmark1286966► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Federal Trade Commission
Mallinckrodt
Cantor Fitzgerald
Teva
US Department of Justice
Johnson and Johnson
Fuji
Deloitte
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot